Adaptive immune resistance provides a strong theoretical basis for the clinical efficacy of PD-1- or PD-L1-blocking antibodies [39], which are able to reactivate an anti-tumor immune response from MHC-restricted T cells through the inhibition of immunological checkpoints [40]. The gene discussed is HLA-C; the disease is neoplasm.